| |
Founded in May 2005, Fovea is an integrated drug discovery and development Company focused on ophthalmic diseases.
Based in Paris, Fovea raised 20.5 M € (25M$) in November 2005 from European top-tier investors during a series A round of financing.
The Company is building upon its core scientific and clinical competency and is complementing its assets with a balanced product pipeline acquired from biotech and pharmaceutical partners and a strong and experienced management team.
Fovea operates within the ophthalmic pharmaceutical market which is expected to grow at a double digit annual rate during the years to come. This growth is likely to be driven by new technologies and products, premium pricing facing no significant reimbursement issues, favorable trends (aging of the population, diabetes epidemiology and environmental factors) and dramatic expansion into the large and mostly untapped market for retinal degenerative diseases.
Fovea Structure : A Product Driven Business Model Company
|
